Category - New Drugs
ViiV Healthcare Announces US FDA Approval of Triumeq PD, the First Dispersible Single Tablet Regimen Containing Dolutegravir, a Once-Daily Treatment for Children Living with HIV
FDA Approves Tlando (testosterone undecanoate) for Male Hypogonadism
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Virologically Suppressed Adolescents Living with HIV Who Are 12 Years of Age or Older and Weigh at Least 35 kg
Fintepla (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)
Novo Nordisk Receives FDA Approval of Higher-Dose Ozempic 2 mg Providing Increased Glycemic Control for Adults with Type 2 Diabetes
ViiV Healthcare Announces Label Update for its Long-Acting HIV Treatment, Cabenuva (cabotegravir, rilpivirine), to be Initiated With or Without an Oral Lead-In Period
FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
FDA Approves Locametz (kit for the preparation of gallium Ga 68 gozetotide injection) for PSMA PET Imaging in Patients with Prostate Cancer